MedPath

heart rate control after acute myocardial infarctio

Phase 4
Recruiting
Conditions
I21
Acute myocardial infarction
Registration Number
DRKS00000766
Lead Sponsor
niversität zu Köln
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
100
Inclusion Criteria

•Acute st-segment elevation myocardial infarction (time between symptom onset and PCI < 6 hours) with successful PCI (TIMI III°)
•Killip Klassification I, II
•Written informed consent
•Resting heart rate = 60 bpm
•Age above 18 years
•Mean blood pressure = 65 mmHg
•Systolic blood pressure > 90mmHg
•Medication with Heparin (weight adapted), clopidogrel ans aspirin before PCI
•SO2 > 90%
•Elevated heart rate (= 60/min)

Exclusion Criteria

•Mean blood pressure < 65 mmHg
•Incomplete PCI success (TIMI < III)
•Cardiogenic shock
•Killip Klassification III, IV
•Symptomatic AV conduction block II°, III°,
sinuatrial conduction block (II°, III°)

•Catecholamin therapy
•Heart rate < 60/min.
•Severe peripheral artery disease (Fontaine > IIb)
•Moderate to severe renal impairment (Serum-creatinin > 2 mg/100ml)
•Severe liver dysfunction
•Severe acidosis (pH < 7,2)
•Known contraindications for Brevibloc (e.g. asthma bronchiale) or known intolerance to Brevibloc
•Participation in other interventional studies
•Person related to the sponsor or investigator
•Subjects who were not eligible for follow-up visits (e.g. due to long distance between study hospital and home adress)
•Women in whom a pregnancy cannot excluded
•Missing safe contraception (hormonal or copper spirale)
•Patients without guidelines recommended therapy previosly to PCI
•Patients in whom anamnestic the symptom onset was > 6 hours or first laboratory tests indicate (LDH > 280U/I) that the myocardial infarction onset was more than 6 hours and in whom no other reasons for elevated LDH are present.
•Unsuccessful PCI
•Symptom onset > 6 hours

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath